Successful use of tofacitinib in reactive arthritis following COVID-19 infection
Indian Journal of Rheumatology
; 18(1):96-97, 2023.
Article
in English
| EMBASE | ID: covidwho-2301387
add on therapy; adult; ageusia; ambient air; anorexia; case report; clinical article; coronavirus disease 2019/di [Diagnosis]; disease activity score; disease duration; dry cough; erythrocyte sedimentation rate; fatigue; ferritin blood level; fever; follow up; hemoglobin blood level; home quarantine; human; latent tuberculosis; letter; leukocyte count; male; middle aged; myalgia; nasopharyngeal swab; oxygen saturation; physical examination; reactive arthritis/di [Diagnosis]; reactive arthritis/dt [Drug Therapy]; sore throat; treatment response; antihistaminic agent; C reactive protein/ec [Endogenous Compound]; diclofenac; ferritin/ec [Endogenous Compound]; hemoglobin/ec [Endogenous Compound]; interleukin 17/ec [Endogenous Compound]; interleukin 6/ec [Endogenous Compound]; methotrexate/cb [Drug Combination]; methotrexate/po [Oral Drug Administration]; nonsteroid antiinflammatory agent/cb [Drug Combination]; paracetamol; prednisolone; salazosulfapyridine; tofacitinib/dt [Drug Therapy]; triamcinolone/ar [Intraarticular Drug Administration]; tumor necrosis factor/ec [Endogenous Compound]; SARS coronavirus 2 nucleic acid test kit
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Indian Journal of Rheumatology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS